Forest Laboratories

On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories, creating one of the world’s fastest-growing specialty pharmaceutical companies with annual revenues of more than $15 billion anticipated for 2015.

The combination of Actavis and Forest creates a new breed of specialty pharmaceutical company, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and a flexible, scalable business model that permits it to adapt quickly to ever-changing industry dynamics and drive sustainable, long-term organic growth.

On a pro forma combined basis for full year 2014, Actavis’ brand pharmaceutical business now includes an approximately $2 billion CNS franchise; gastroenterology and women's health franchises valued at approximately $1 billion each; a cardiovascular franchise that generates approximately $500 million; and urology and dermatology/established brand franchises approaching $500 million a year in sales each; as well as emerging and sustainable portfolios in the infectious disease and respiratory therapeutic categories.

Its key marketed brands include Bystolic (nebivolol), Daliresp(roflumilast), Fetzima(levomilnacipran extended-release capsules), Linzess(linaclotide), Namenda(memantine HCl), Namenda XR (memantine HCl), Saphris(asenapine), Savella(milnacipran HCl), Teflaro(ceftaroline fosamil) for injection, TudorzaPressair(aclidinium bromide inhalation powder), and Viibryd(vilazodone HCl).


Latest Articles

Latest News

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top